For Healthcare Professionals

A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

clipboard-pencil

About the study

A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab and bevacizumab therapy in patients with locoregional hepatocellular carcinoma
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. No evidence of extrahepatic disease
  2. Disease not amenable to curative surgery or transplantation or curative ablation but disease amenable to TACE
  3. Child-Pugh score class A to B7 and Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment
  4. Measurable disease by Modified Response Criteria in Solid Tumors (mRECIST) criteria
  5. Adequate organ and marrow function Key

EXCLUSION CRITERIA

    pin location

    Study Locations

    Enter your ZIP code/Postal code/PIN code to locate study sites near you:

    How to Apply


    Contact the study center to learn if this study is a good match for you.
    Phone iconCall 1-877-240-9479Email iconEmail Study Center

    Study’s details


    Contition

    Hepatocellular Carcinoma

    Age

    18+

    Phase

    Phase 3

    Participants needed

    724

    Est. Completion Date

    Aug 2024

    Treatment type

    Interventional


    Sponsor

    AstraZeneca

    ClinicalTrials.gov identifier

    NCT03778957

    Study number

    D933GC00001

    Understanding Clinical Trials


    Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
    Vector

    Interested?

    Sign up to save your favorites, 
    receive newsletters, resources, and alerts 
    about clinical trials related to your conditions of interest.